Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          

LT1001

LT1001

A Novel 7-Day Analgesic Injection

Request for Collaboration
Overview
LT1001 is the first long-acting analgesic injection containing dinalbuphine sebacate, a prodrug of nalbuphine, in an oil-based formulation intended for sustained release of the drug. Nalbuphine is a κ-agonist / partial μ-antagonist analgesic with an analgesic effect comparable to that of morphine, yet it has a ceiling effect on respiratory depression.  LT1001 was designed to take advantages of nalbuphine's safety profile, and overcome the disadvantage of nalbuphine relatively short half-life. While most pain medications relieve pain for 2 to 6 hours, LT1001 exerts its analgesic effect for up to a week. In a post-operative setting, it will signifcantly increase pain patients' quality of life, reduce health care resource, thus deliver a high pharmacoeconomic value. LT1001 is currently under the evaluation for NDA by the Taiwan FDA.
Application
Ceiling Effect on Respiratory Depression
LT1001 is a prodrug of nalbuphine, a semisynthetic opioid compound behaves as a κ-agonist / partial μ-antagonist. It exhibits a ceiling effect on respiratory depression; i.e., an increase in dose greater than 30 mg does not produce further respiratory depression.

Differentiating Characteristics
-Indicated for moderate to severe pain with an analgesic effect comparable to morphine
-Ceiling effect on respiratory depression, greatest safety concern for other opioids
-Not a controlled substance in the U.S. – low risk of addiction or substance abuse
-Long-acting analgesics; improve patient QoL while minimizing health care burden
Patent Portfolio
In additional to the know-how in API synthesis and finish product manufacturing, LT1001 was granted patents in USA, Europe, Japan, Korea, China and several other major markets. Additional related patents have been filed/under preparation for market protection up to 2036.
Collaboration Options
Actively seeking global licensees for tech-transfer agreements in the markets and territories outside Taiwan, China, Hong Kong, and Macau.
People who like this also like
  • Prenatal diagnosis by Oligonucleotide array-comparative genomic hybridization analysis testPrenatal diagnosis by Oligonucleotide array-comparative genomic hybridization analysis test
  • PHDC-01PHDC-01
  • SB02SB02
  • SNP-610SNP-610
  • FuraprevirFuraprevir
  • Platform_Polymeric MicellePlatform_Polymeric Micelle
  • TLC177TLC177
  • TLC178TLC178
  • PixoTest technologyPixoTest technology
  • SB05SB05